ArticleJournal of medicinal chemistry2021
First-in-Class Inhibitors of the Ribosomal Oxygenase MINA53.
Open access · hybridAbstract read
In one paragraph
Article in Journal of medicinal chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 16 citations in OpenAlex.
- Profiling Inhibitor Scaffolds for the Cancer Target Jumonji-C Domain-Containing Protein 6.ChemMedChem · 2025Article
- The selective prolyl hydroxylase inhibitor IOX5 stabilizes HIF-1α and compromises development and progression of acute myeloid leukemia.Nature cancer · 2024Article
- 5-Substituted Pyridine-2,4-dicarboxylate Derivatives Have Potential for Selective Inhibition of Human Jumonji-C Domain-Containing Protein 5.Journal of medicinal chemistry · 2023Article
- Kinetic and inhibition studies on human Jumonji-C (JmjC) domain-containing protein 5.RSC chemical biology · 2023Article
- First-in-Class Selective Inhibitors of the Lysine Acetyltransferase KAT8.Journal of medicinal chemistry · 2023Article
- Substrate selectivity and inhibition of histidine JmjC hydroxylases MINA53 and NO66.RSC chemical biology · 2023Article
- Pharmacological targeting of CBP/p300 drives a redox/autophagy axis leading to senescence-induced growth arrest in non-small cell lung cancer cells.Cancer gene therapy · 2023Article
- MDIG, a 2‑oxoglutarate‑dependent oxygenase, acts as an oncogene and predicts the prognosis of multiple types of cancer.International journal of oncology · 2022Article
- 2-Oxoglutarate derivatives can selectively enhance or inhibit the activity of human oxygenases.Nature communications · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 7 institutions in 3 countries.
Radosław P NowakBotnar Research Centre, Nuffield Orthopaedic Centre, University of Oxford, Headington OX3 7LD, U.K.ORCID 0000-0002-0605-0071
Anthony TumberBotnar Research Centre, Nuffield Orthopaedic Centre, University of Oxford, Headington OX3 7LD, U.K.
Eline HendrixInstitute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, U.K.
Mohammad Salik Zeya AnsariInstitute of Molecular Biology and Pathology (IMBP), National Research Council (CNR) c/o Department of Biology and Biotechnology "Charles Darwin" Sapienza University of Rome, Via degli Apuli 4, Rome 00185, Italy.
Manuela SabatinoRome Center for Molecular Design, Department of Chemistry and Technology of Drugs, ″Sapienza″ University of Rome, Piazzale Aldo Moro 5, Rome 00185, Italy.
Lorenzo AntoniniRome Center for Molecular Design, Department of Chemistry and Technology of Drugs, ″Sapienza″ University of Rome, Piazzale Aldo Moro 5, Rome 00185, Italy.
Regina AndrijesInstitute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, U.K.
Eidarus SalahChemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, 12, Mansfield Road, University of Oxford, Oxford OX1 3TA, U.K.
Nicola MautoneDepartment of Chemistry and Technology of Drugs, ″Sapienza″ University of Rome, Piazzale Aldo Moro 5, Rome 00185, Italy.
Francesca Romana PellegriniInstitute of Molecular Biology and Pathology (IMBP), National Research Council (CNR) c/o Department of Biology and Biotechnology "Charles Darwin" Sapienza University of Rome, Via degli Apuli 4, Rome 00185, Italy.
Klemensas SimelisChemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, 12, Mansfield Road, University of Oxford, Oxford OX1 3TA, U.K.
Akane KawamuraChemistry - School of Natural and Environmental Sciences, Newcastle University, Newcastle upon Tyne NE1 7RU, U.K.ORCID 0000-0003-1169-5082
Catrine JohanssonBotnar Research Centre, Nuffield Orthopaedic Centre, University of Oxford, Headington OX3 7LD, U.K.
Daniela PasseriTES Pharma S.r.l. Via P. Togliatti 20, Corciano, Perugia 06073, Italy.
Roberto PellicciariTES Pharma S.r.l. Via P. Togliatti 20, Corciano, Perugia 06073, Italy.
Alessia CiogliDepartment of Chemistry and Technology of Drugs, ″Sapienza″ University of Rome, Piazzale Aldo Moro 5, Rome 00185, Italy.
Donatella Del BufaloPreclinical Models and New Therapeutic Agents Unit, IRCCS-Regina Elena National Cancer Institute, Via Elio Chianesi 53, Rome 00144, Italy.
Rino RagnoRome Center for Molecular Design, Department of Chemistry and Technology of Drugs, ″Sapienza″ University of Rome, Piazzale Aldo Moro 5, Rome 00185, Italy.ORCID 0000-0001-5399-975X
Mathew L ColemanInstitute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, U.K.
Daniela TrisciuoglioInstitute of Molecular Biology and Pathology (IMBP), National Research Council (CNR) c/o Department of Biology and Biotechnology "Charles Darwin" Sapienza University of Rome, Via degli Apuli 4, Rome 00185, Italy.
Antonello MaiDepartment of Chemistry and Technology of Drugs, ″Sapienza″ University of Rome, Piazzale Aldo Moro 5, Rome 00185, Italy.ORCID 0000-0001-9176-2382
Udo OppermannBotnar Research Centre, Nuffield Orthopaedic Centre, University of Oxford, Headington OX3 7LD, U.K.ORCID 0000-0001-9984-5342
Christopher J SchofieldChemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, 12, Mansfield Road, University of Oxford, Oxford OX1 3TA, U.K.ORCID 0000-0002-0290-6565
Dante RotiliDepartment of Chemistry and Technology of Drugs, ″Sapienza″ University of Rome, Piazzale Aldo Moro 5, Rome 00185, Italy.ORCID 0000-0002-8428-8763
Sapienza University of Rome · ITMansfield University · USInstitute of Molecular Biology and Pathology · ITUniversity of Birmingham · GBNuffield Orthopaedic Centre · GBIstituti di Ricovero e Cura a Carattere Scientifico · ITNewcastle University · GB
Funding
Biotechnology and Biological Sciences Research Council BB/L009846/1Cancer Research UK 24552Cancer Research UK 28285Cancer Research UK A23900Cancer Research UK C33483/A25674Cancer Research UK C8717/A18245Medical Research Council MR/N021053/1Wellcome TrustWellcome Trust 106244/Z/14/Z
Abstract
MINA53 is a JmjC domain 2-oxoglutarate-dependent oxygenase that catalyzes ribosomal hydroxylation and is a target of the oncogenic transcription factor
Indexed as
Cell Line, TumorCell ProliferationCrystallizationDioxygenasesEnzyme InhibitorsHistone DemethylasesHumansModels, MolecularNuclear ProteinsProtein ConformationRibosomesSubstrate SpecificityDioxygenasesEnzyme InhibitorsHistone DemethylasesNuclear ProteinsRIOX2 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.